9-month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis
Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
We aim to assess the effect of Ofatumumab on microglial activation using [F-18]PBR06 PET in
MS patients in relation to changes in serum markers, MRI abnormalities and clinical
impairment longitudinally over 9 months.
Specific Aims:
Specific Aim 1: To determine the effect of Ofatumumab on microglial activation in MS over 9
months.
Specific Aim 2: To determine the time course of effect of Ofatumumab on microglial activation
and its relationship with peripheral B-cell depletion, serum neurofilament light (sNfL) chain
and glial-fibrillary acid protein (GFAP) levels and other serum biomarkers
Specific Aim 3: To determine the relationship of PET changes following Ofatumumab initiation
with 3T MRI changes and clinical parameters.